medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (3)

Fusion transcripts of the PML/RARα gene in patients with promyelocytic leukemia

Barroso SG, Hernández PC, Garrote SH

Language: Spanish
References: 34
Page: 1-14
PDF size: 729.90 Kb.


ABSTRACT

Introduction: Promyelocytic leukemia is considered a well-defined entity due to its peculiar clinical, morphological, cytogenetic and molecular characteristics. The discovery of the oncogenetic mechanisms involved in the genesis of the disease makes this variant of leukemia one of the most relevant models for translational research.
Objective: To characterize the fusion transcripts of the PML/RARα gene in patients with promyelocytic leukemia.
Methods: An observational, ambispective, descriptive, longitudinal investigation was carried out in patients diagnosed with promyelocytic leukemia at the Institute of Hematology and Immunology, between January 2001 and December 2020. The sample consisted of 105 patients who met the criteria for inclusion and exclusion.
Results: There is no relationship between the transcripts and age, sex, skin color and clinical characteristics. The presence of the bcr3 fusion transcript was associated with higher hemoglobin levels and lower platelet counts. The incidence of relapse was not related to fusion transcripts and their influence on overall survival in patients with promyelocytic leukemia was not proven.
Conclusions: The fusion transcripts´scharacteristicsof the PML/RARα gene are similar to international reports, especially from populations of Latin origin.


REFERENCES

  1. Jimenez JJ, Chale RS, Abad AC, Schally AV. Acute promyelocytic leukemia (APL): a review of the literature. Oncotarget1. . 2020;11(11):992-1003. DOI: https:// 10.18632/oncotarget.27513

  2. Thomas X. Acute Promyelocytic Leukemia: A History over 60 Years: From the Most Malignant to the most Curable Form of Acute Leukemia. Oncol Ther. 2019;(7):[pages]33-65[/pages]. DOI: https://doi.org/10.1007/s402.

  3. Ng CH, Chng WJ. Recent advances in acute promyelocytic leukaemia. F1000Res. 2017; 6:1273. DOI: https:// 10.12688/f1000research.10736.1

  4. Barroso Sánchez G, Hernández Padrón C. Terapia dirigida a dianas moleculares: perspectiva actual en la leucemia promielocítica. Rev cubana Hematol Inmunol Hemoter. 2021[acceso 19/07/2021];37(3). Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/1481 4.

  5. Ryan MM. Acute Promyelocytic Leukemia: A Summary. J Adv Pract Oncol. 2018;9(2):178-87.

  6. De Thé H, Pandolfi PP, Chen Z. Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. Cancer cell. 201732(5), 552-60. DOI: https:// 10.1016/j.ccell.2017.10.002

  7. Walasek A. The new perspectives of targeted therapy in acute myeloid leukemia. Adv Clin Exp Med. 2019;28(2):271-6. DOI: https:// 10.17219/acem/81610

  8. Amor Vigil AM, Lavaut Sánchez K, Díaz Alonso CA. Técnicas de citogenética y biología molecular para el diagnóstico y seguimiento de la leucemia promielocítica. Rev Cubana Hematol Inmunol Hemoter. 2021[acceso 19/07/2021];37(3). Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/1375 8.

  9. Zhu HH, Liu YR, Qin YZ. Detecting PML-RAR alpha transcript in acute promyelocytic leukemia using real-time quantitative RT-PCR. Chin Med J (Engl). 2007;120(20):1803-8.

  10. Jurcic JG. Monitoring PML-RAR alpha in acute promyelocytic leukemia. CurrOncol Rep. 2003;5(5):391-8. DOI: https:// 10.1007/s11912-003-0025-7

  11. Martínez Antuña G, Cayado Gutiérrez N, Muñiz Fernández A, Espinosa Martínez E, Dorticós Balea E, González Otero A et al11. . Diagnóstico molecular de la leucemia aguda promielocítica: Resultados preliminares. Rev Cubana Hematol Inmunol Hemoter. 2000[acceso 21/07/2021];16(2):125-31. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892000000200007&lng=es 11. .

  12. Noguera NI, Catalano G, Banella C, Divona M, Faraoni I, Ottone T, et al12. . Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies. Cancers (Basel). 2019;11(10):1591. DOI: https:// 10.3390/cancers11101591

  13. Amor Vigil AM, Hernández Miranda LL, Díaz Alonso CA, Fernández Martínez L, Ruíz Moleón V, Garrote Santana H. La biología molecular en la precisión diagnóstica de las leucemias. Rev Cubana Hematol Inmunol Hemoter. 2018[acceso 20/07/2021];34(3). Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/882 13.

  14. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-4.

  15. Biondi A, Luciano A, Bassan R, Mininni D, Specchi G, Lanzi E. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. Leukemia. 1995; 9:1461

  16. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A Diverio D. Genomic variability and alternative splicing generate multiple PML/RARa transcripts in consistent that encode aberrant PML proteins and PML/RARa isoforms involving a cutepromyelocyticleukaemia. EMBO J 1992;Our 11:1397

  17. Mandelli F, Diverio D, Avvisati G. Molecular remission in PML/RAR positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90: 1014-1021.

  18. González M, Barragan E, Bolufer P, Chillon C, Colomer D, Borstein R, et al18. . Spanish programme for the study and treatment of haematological malignancies (PETHEMA) group. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia according to the PML- RARa isoforms: a study of the PETHEMA group. Br J Haematol. 2001. 114:99-103.

  19. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, et al19. . Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997;90(4):1656-63.

  20. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al20. . United states multicenter study of arsenic trioxide in relapsed acute promyelocytic leukaemia. J Clin Oncol. 2001;19:3852-60.

  21. Wen L, Xu Y, Yao L, Wang N, Wang Q, Liu T, et al21. . Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions. Haematologica. 2019;104(5):e195-9. DOI: https:// 10.3324/haematol.2018.205369

  22. Fukutani H, Naoe T, Ohno R, Yoshida H, Miyawaki S, Shimazaki C, et al22. . Isoforms of PML-retinoic acid receptor Alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia or prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1995;9(9):1478-82.

  23. Fasan A, Haferlach C, Perglerovà K, Kern W, Haferlach T. Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse. Haematologica2017;102:e224. DOI: https:// 10.3324/haematol.2016.162206

  24. Melo RA, de Vasconcellos JF, Melo FC, Machado CG, Lacerda TM, Souto FR. PML-RAR alpha fusion gene transcripts and biological features in acute promyelocytic leukemia patients. Clin Lab Haematol. 2006;28(2):126-9. DOI: https:// 10.1111/j.1365-2257.2006.00763.X

  25. Silva WFD Jr, Rosa LID, Marquez GL, Bassolli L, Tucunduva L, Silveira DRA, et al25. . Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil - Early Deaths Are Still a Problem. Clin Lymphoma Myeloma Leuk. 2019;19(2):e116-22. DOI: https:// 10.1016/j.clml.2018.11.004

  26. Chen SJ, Chen Z, Chen A, Tong JH, Dong S, Wang ZY, et al26. . Occurrence of distinct PML-RAR fusion gene isoforms in patients with acute promyelocytic leukaemia detected by reverse transcriptase/polymerase chain reaction. Oncogene. 1992;7:1223-32.

  27. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukaemia breakpoint cluster region on chromosome 17. Science. 1990;249:1577-80

  28. Slack JL, Willman CL, Andersen JW, Li YP, Viswanatha DS, Bloomfield CD, et al28. . Molecular analysis and clinical outcome of adult APL patients with the type V PML-RAR alpha isoform: results from intergroup protocol 0129. Blood. 2000;95(2):398-403.

  29. Lin X, Qiao N, Shen Y, Fang H, Xue Q, Cui B, et al29. . Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia. Clin Cancer Res. 2021;27(13):3683-94. DOI: https:// 10.1158/1078-0432.CCR-20-4375

  30. Wen L, Xu Y, Yao L, Wang N, Wang Q, Liu T, et al30. . Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions. Haematologica. 2019;104(5):e195-9. DOI: https:// 10.3324/haematol.2018.205369

  31. Fasan A, Haferlach C, Perglerovà K, Kern W, Haferlach T. Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse. Haematologica2017;102:e224. DOI: https:// 10.3324/haematol.2016.162206

  32. Rasekh EO, Elsayed GM, Madney Y, El Gammal MM. Prognostic Significance of bcr-1 and bcr-3 Isoforms of PML-RARA and FLT3-ITD in Patients with Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(3):156-67. DOI: https:// 10.1016/j.clml.2019.08.006

  33. Silveira DRA, Quek L, Santos IS, Corby A, Coelho-Silva JL, Pereira-Martins DA, et al33. . Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Adv. 2020;4(10):2339-50. DOI: https:// 10.1182/bloodadvances.2019001419

  34. Azevedo IF, Magalhães MG, Souto FR, Neves WB, Melo FC, Rego EM, et al34. . Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study. Rev Bras Hematol Hemoter. 2017;39(1):46-51. DOI: https:// 10.1016/j.bjhh.2016.09.010




2020     |     www.medigraphic.com